Literature DB >> 11501840

Human herpesviruses HHV-4 (EBV) and HHV-6 in Hodgkin's and Kikuchi's diseases and their relation to proliferation and apoptosis.

G R Krueger1, M L Huetter, J Rojo, M Romero, H Cruz-Ortiz.   

Abstract

BACKGROUND: Human herpesviruses types 4 and 6 (EBV, HHV-6) are frequently found in Hodgkin 's disease (HD) and--to a certain extent--in Kikuchi-Fujimoto's disease (KFD). Both viruses are apparently related to proliferative and/or apoptotic processes as represented by HD or KFD respectively.
OBJECTIVE: To correlate frequency and location of antigen- and DNA expression of both viruses in HD and KFD tissue sections in relation to markers for cell proliferation and apoptosis. STUDY
DESIGN: Archival lymph node biopsies from 103 patients with HD and 14 KFD patients were investigated immunohistologically for viral antigen expression (EBV LMP- 1: HHV-6 pl 10/60), Ki67/PCNR, marker for proliferation (MIB1)/p53 and WAF1 for apoptosis. Viral DNA was shown by in situ hybridization. Apoptosis was determined by ISEL and TUNEL techniques.
RESULTS: HD is frequently infected by both EBV and HHV-6 while KFD tends to be infected only by HHV-6. EBV in HD is present in HD cells and in Reed-Sternberg cells (HD/RS cells), HHV-6 preferentially in lymphocytes and in histiocytes in both HD and in KFD. Proliferation marker Ki67 is found in lymphocytes and histiocytes of both diseases and in HD and RS cells in HD. Apoptosis is demonstrated in lymphocytes and histiocytes preferentially in KFD and to a lesser extent also in HD.
CONCLUSION: Although EBVand HHV-6 may not be openly oncogenic in HD and KFD, they may well influence the course of the disease. Dual infection in HD appears to support proliferative processes, i.e. a predominance of EBV effects. Single infection with HHV-6 in KFD instead appears to favor an apoptotic course. These effects are--according to the literature--possibly cytokine-mediated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11501840

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  U20 is responsible for human herpesvirus 6B inhibition of tumor necrosis factor receptor-dependent signaling and apoptosis.

Authors:  Emil Kofod-Olsen; Katrine Ross-Hansen; Mariane Høgsbjerg Schleimann; Dea Kejlberg Jensen; Janni Michelle Lund Møller; Bettina Bundgaard; Jacob Giehm Mikkelsen; Per Höllsberg
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Kikuchi-fujimoto disease in a 30-year-old caucasian female.

Authors:  David J Archibald; Matthew L Carlson; Ray O Gustafson
Journal:  Int J Otolaryngol       Date:  2009-12-20

4.  Detection of human herpesvirus DNA in Kikuchi-Fujimoto disease and reactive lymphoid hyperplasia.

Authors:  S David Hudnall; Tiansheng Chen; Samir Amr; Ken H Young; Kristin Henry
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 5.  Human herpesvirus 6 infections after liver transplantation.

Authors:  Rima Camille Abdel Massih; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

6.  β-HHVs and HHV-8 in Lymphoproliferative Disorders.

Authors:  C Quadrelli; P Barozzi; G Riva; D Vallerini; E Zanetti; L Potenza; F Forghieri; M Luppi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

Review 7.  Human Herpesvirus 6 and Malignancy: A Review.

Authors:  Eva Eliassen; Emily Lum; Joshua Pritchett; Joseph Ongradi; Gerhard Krueger; John R Crawford; Tuan L Phan; Dharam Ablashi; Stanley David Hudnall
Journal:  Front Oncol       Date:  2018-11-13       Impact factor: 6.244

8.  Histiocytic necrotising lymphadenitis (Kikuchi-Fujimoto disease) in Saudi Arabia: clinicopathology and immunohistochemistry.

Authors:  Jaudah Al-Maghrabi; Hassan Kanaan
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.